Samia Zuhair Sabbagh

Samia Zuhair Sabbagh

Auto-generated profile, based on publicly available information

Samia Zuhair Sabbagh

Pharmacy Program Batterjee Medical College Jeddah Saudi Arabia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2026 in Cancer Medicine
Verified
Journal Article
Open access
DADana Abou
Dana Abou
HTHusna Irfan Thalib
Husna Irfan Thalib
FAFayza Akil
Fayza Akil
SSSamia Zuhair Sabbagh
Samia Zuhair Sabbagh
HAHala Sofian Abou
Hala Sofian Abou
FHfatma hassan
fatma hassan
Introduction: Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (rel/ref) disease. This subgroup has historically faced poor prognoses with limited treatment options, prompting the development of novel immunotherapeutic strategies. Chimeric antigen receptor T‐cell (CAR T) therapy and bispecific antibodies (BsAbs) have emerged as transformative approaches in this setting. Methods: This narrative review compares these therapies across multiple domains, including mechanisms of action, clinical efficacy, safety profiles, logistics, cost, and accessibility. Results: CAR T therapies have demonstrated durable complete response rates (40%–60%) and extended progression‐free survival (median 11–12.5 months), but they are limited by complex manufacturing, high cost, and potentially severe toxicities. In contrast, BsAbs offer immediate, off‐the‐shelf availability, with promising efficacy and a more favorable safety profile that enables outpatient administration, although long‐term durability remains under investigation. Conclusion: This review provides clinicians with a comprehensive comparison to support evidence‐based treatment selection in rel/ref DLBCL.